Genetics:研究者揭示连接糖尿病和阿尔兹海默症的共同基因

2012-06-18 T.Shen 生物谷

近日,来自纽约城市大学的研究者研究发现,存在于阿尔茨海默症患者机体的基因可以影响其胰岛素途径。这个途径的破坏将会是引发糖尿病的一个标志,相关研究成果刊登在了近日的国际著名杂志Genetics上,这将为开发一些靶向治疗方法提供了线索和希望。 II型糖尿病患者存在高的痴呆风险,胰岛素途径介导了很多代谢过程,包括帮助维持神经系统的健康等等。目前尽管阿尔兹海默症的原因尚不清楚,但是目前患者死后诊断的标准

近日,来自纽约城市大学的研究者研究发现,存在于阿尔茨海默症患者机体的基因可以影响其胰岛素途径。这个途径的破坏将会是引发糖尿病的一个标志,相关研究成果刊登在了近日的国际著名杂志Genetics上,这将为开发一些靶向治疗方法提供了线索和希望。

II型糖尿病患者存在高的痴呆风险,胰岛素途径介导了很多代谢过程,包括帮助维持神经系统的健康等等。目前尽管阿尔兹海默症的原因尚不清楚,但是目前患者死后诊断的标准是患者大脑中的淀粉样蛋白的粘性斑是否存在。人类淀粉样前蛋白(APP)的突变或者处理APP基因的突变揭示出阿尔兹海默症会在家族中流行。这项研究中,研究者Li和其同事研究了蛋白质APL-1,该蛋白由基因秀丽隐杆线虫的基因编码。

研究者表示,他们的发现秀丽隐杆线虫等价APP基因的突变可以减缓其发育的速度,这就解释了某些代谢途径是被破坏掉的。研究者将开始研究等价APP基因是如何同时调节不同的代谢途径以及如何影响胰岛素途径的。研究者表示APL-1蛋白异常重要,当敲除了秀丽隐杆线虫的等价APP基因,动物就会死亡,这就告诉我们APP基因家族蛋白对于线虫是必不可少的,正如APP基因在哺乳动物中也是很重要的。

这项研究中,研究者揭示了糖尿病患者和阿尔兹海默症患者的联系,然而这种蛋白质碎片和胰岛素途径有关系,每一个碎片蛋白都会吸附并且给神经元传导信号。后期研究者还会深入研究其具体的机制。

编译自:Gene may link diabetes and Alzheimer's, researchers find

编译者:天使托

doi:10.1534/genetics.112.138768
PMC:
PMID:

APL-1, the Alzheimer’s Amyloid Precursor Protein in Caenorhabditis elegans, Modulates Multiple Metabolic Pathways Throughout Development

Collin Y. Ewald1, Daniel A. Raps2 and Chris Li1,*

Mutations in the amyloid precursor protein (APP) gene or in genes that process APP are correlated with familial Alzheimer’s disease. The biological function of APP remains unclear. APP is a transmembrane protein that can be sequentially cleaved by different secretases to yield multiple fragments, which can potentially act as signaling molecules. Caenorhabditis elegans encodes one APP-related protein, APL-1, which is essential for viability. Here, we show that APL-1 signaling is dependent on the activity of the FOXO transcription factor DAF-16 and the nuclear hormone receptor DAF-12 and influences metabolic pathways such as developmental progression, body size, and egg-laying rate. Furthermore, apl-1(yn5) mutants, which produce high levels of the extracellular APL-1 fragment, show an incompletely penetrant temperature-sensitive embryonic lethality. In a genetic screen to isolate mutants in which the apl-1(yn5) lethality rate is modified, we identified a suppressor mutation in MOA-1/R155.2, a receptor-protein tyrosinephosphatase, and an enhancer mutation in MOA-2/B0495.6, a protein involved in receptormediated endocytosis. Knockdown of apl-1 in an apl-1(yn5) background caused lethality and molting defects at all larval stages, suggesting that apl-1 is required for each transitional molt. We suggest that signaling of the released APL-1 fragment modulates multiple metabolic states and that APL-1 is required throughout development.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685861, encodeId=6d411685861cd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 06:52:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048443, encodeId=93242048443bc, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 06 04:52:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877927, encodeId=9b9018e792747, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Aug 12 06:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733600, encodeId=06461e336003b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Sep 04 10:52:00 CST 2012, time=2012-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032701, encodeId=853c2032e012b, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jul 14 12:52:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402633, encodeId=b954140263317, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685861, encodeId=6d411685861cd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 06:52:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048443, encodeId=93242048443bc, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 06 04:52:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877927, encodeId=9b9018e792747, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Aug 12 06:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733600, encodeId=06461e336003b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Sep 04 10:52:00 CST 2012, time=2012-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032701, encodeId=853c2032e012b, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jul 14 12:52:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402633, encodeId=b954140263317, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-07-06 cy0324
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685861, encodeId=6d411685861cd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 06:52:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048443, encodeId=93242048443bc, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 06 04:52:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877927, encodeId=9b9018e792747, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Aug 12 06:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733600, encodeId=06461e336003b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Sep 04 10:52:00 CST 2012, time=2012-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032701, encodeId=853c2032e012b, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jul 14 12:52:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402633, encodeId=b954140263317, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-08-12 huperzia
  4. [GetPortalCommentsPageByObjectIdResponse(id=1685861, encodeId=6d411685861cd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 06:52:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048443, encodeId=93242048443bc, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 06 04:52:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877927, encodeId=9b9018e792747, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Aug 12 06:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733600, encodeId=06461e336003b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Sep 04 10:52:00 CST 2012, time=2012-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032701, encodeId=853c2032e012b, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jul 14 12:52:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402633, encodeId=b954140263317, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-09-04 canlab
  5. [GetPortalCommentsPageByObjectIdResponse(id=1685861, encodeId=6d411685861cd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 06:52:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048443, encodeId=93242048443bc, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 06 04:52:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877927, encodeId=9b9018e792747, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Aug 12 06:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733600, encodeId=06461e336003b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Sep 04 10:52:00 CST 2012, time=2012-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032701, encodeId=853c2032e012b, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jul 14 12:52:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402633, encodeId=b954140263317, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]
    2012-07-14 stfoxst
  6. [GetPortalCommentsPageByObjectIdResponse(id=1685861, encodeId=6d411685861cd, content=<a href='/topic/show?id=66f3e93862' target=_blank style='color:#2F92EE;'>#Genet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7938, encryptionId=66f3e93862, topicName=Genet)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d3e128296421, createdName=江川靖瑶, createdTime=Tue Nov 27 06:52:00 CST 2012, time=2012-11-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2048443, encodeId=93242048443bc, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Fri Jul 06 04:52:00 CST 2012, time=2012-07-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1877927, encodeId=9b9018e792747, content=<a href='/topic/show?id=5d80e943ef' target=_blank style='color:#2F92EE;'>#Genetics#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7943, encryptionId=5d80e943ef, topicName=Genetics)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Aug 12 06:52:00 CST 2012, time=2012-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1733600, encodeId=06461e336003b, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Tue Sep 04 10:52:00 CST 2012, time=2012-09-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032701, encodeId=853c2032e012b, content=<a href='/topic/show?id=ff85e343730' target=_blank style='color:#2F92EE;'>#研究者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73437, encryptionId=ff85e343730, topicName=研究者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Sat Jul 14 12:52:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1402633, encodeId=b954140263317, content=<a href='/topic/show?id=60ca9e761ce' target=_blank style='color:#2F92EE;'>#阿尔兹海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97761, encryptionId=60ca9e761ce, topicName=阿尔兹海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=be952422716, createdName=habb, createdTime=Wed Jun 20 09:52:00 CST 2012, time=2012-06-20, status=1, ipAttribution=)]

相关资讯

JAMA:先进的诊断性成像及相关的辐射接触有了大幅的增加

芝加哥–据6月13日刊《美国医学会杂志》JAMA上的一项研究披露,在1996-2010年间,在6个大型的综合医疗保健系统中,先进的诊断性成像的使用有了大幅的增加,其中包括电脑断层扫描的使用增加了近3倍及核磁共振成像的使用增加了近4倍,而预计的辐射接触也有了显著的增加。 根据文章的背景资料:“在过去的20年内,医疗保险人群中的诊断性成像的使用有了显著的增加,特别是那些昂贵的诸如电脑断层扫描(CT)

J Nuc Med:新疗法延长前列腺癌病人的生命

佛罗里达州迈阿密海滩——有已经扩散到骨的晚期肿瘤的前列腺癌病人的生存机会很差。参加美国核医学学会(Society of Nuclear Medicine)2012年会的科研人员说,一种新型放射性同位素疗法可能会让患这种病的病人活得更长。 骨骼系统是前列腺癌病人的第一位的转移部位。癌的骨转移发生在原发癌通过血液被输送到骨并且在那里发育的时候。这是一项对氯化镭-223或Ra-223的放射性同位素的I

PNAS:利用锌指核酸酶技术建立寡核苷酸突变疾病模型

利用锌指核酸酶技术(zinc-finger nucleases)在一细胞期的胚胎中进行基因打靶是一种高效的诱变方式,这种方法可以应用在小鼠、大鼠和家兔中。最近该技术被用在了基因插入和基因敲除上。 本文中,研究人员利用锌指核酸酶技术制造疾病相关的基因突变。通过提供同源重组的模板,在Rab38基因上引入了寡核苷酸突变。Rab38基因编码一个小的鸟苷三磷酸酶,这些酶的作用是调节胞内囊泡运输。以前的研究

JACC:血糖水平升高导致患心脏病风险增加

近日,一项哥本哈根大学的最新研究表明:血液中的葡萄糖水平增高会导致增加缺血性心脏病风险增高。这项研究涉及超过80,000人,研究论文发表在Journal of the American College of Cardiology杂志上。这项哥本哈根大学的新研究显示血糖略有升高对非糖尿病人罹患缺血性心脏病有一个更显著的风险。 研究团队对这些结果感到惊讶,因为到现在为止胆固醇被普遍认为是全球心脏健康

PLoS ONE:GPx3酶有助预防心血管疾病

近日,明尼苏达医学院的研究人员与公共卫生学院合作发现一种酶,该酶在较高水平以及高密度脂蛋白(好胆固醇)水平低时,可以大大降低风险心血管疾病。 这种新发现的酶叫谷胱甘肽过氧化物酶或GPX3,是一种天然抗氧化剂,有助于保护生物体的氧化损伤,有助于机体的自然修复。研究人员发现“好”胆固醇水平高的患者之间,GPX3酶的水平并没有显着性差异。然而,“好”胆固醇水平低的患者,GPX3酶可能对疾病来说是一个益

BMJ:食用黑色巧克力可预防心血管疾病的发生

巧克力爱好者的福音已经降临――新近研究表明,每天食用一块黑巧克力可以降低患中风和心脏病的风险! 在《英国医学杂志》(British Medical Journal)今天刊登的一项研究报告中,蒙纳士大学的研究人员证明了黑巧克力具有降血压、降胆固醇的功效,这对于占澳大利亚总人口 30% 的心血管疾病高危人群而言,真是一个既廉价又美味的防治方法。 蒙纳士大学流行病学与预防医学系的博士生 Ella Z